ORIGINAL ARTICLE

Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma

Naoto Kawabe,* Senju Hashimoto,* Takuji Nakano,* Kazunori Nakaoka,* Aiko Fukui,**† and Kentaro Yoshioka*

*Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University School of Medicine and †Faculty of Pharmacy, Meijo University, Aichi, Japan

Key words

cisplatin, hepatocellular carcinoma, transcatheter arterial chemoembolization, transcatheter arterial infusion chemotherapy.

Accepted for publication 8 May 2021.

Abstract

Background and Aim: This study investigated the efficacy of transcatheter arterial infusion (TAI) chemotherapy with cisplatin combined with transcatheter arterial chemoembolization (TACE). The goal was to prevent intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC), compared with TACE alone, in patients with unresectable HCC.

Methods: We conducted a historical cohort study, which involved 68 unresectable HCC patients. The study was performed on 44 and 24 consecutive patients who underwent TAI using cisplatin combined with TACE using epirubicin and TACE using epirubicin alone, respectively. We performed a propensity score analysis to identify the independent risk factors associated with IDR, and constructed propensity score-adjusted survival curves.

Results: After propensity score-adjusting, the adjusted cumulative IDR rates at 1 and 3 years were 76.8 and 76.8% in TACE alone group, and 21.3 and 73.1% in TACE with TAI group, respectively. TACE alone group had a significantly higher IDR rate in comparison with TACE with TAI group (P = 0.0073). Combined with TAI was associated with preventing IDR after propensity score-adjusting (hazard ratio [HR] 0.40, 95% confidence intervals [CI] 0.17–0.91, P = 0.028). Combined with TAI (HR 0.26, 95% CI 0.10–0.68, P = 0.0056) and Stage ≥III (HR 2.98, 95% CI 1.25–7.12, P = 0.014) were independent IDR predictors after adjusting for significant risk factors with propensity score.

Conclusions: We demonstrated that cisplatin TAI accompanied with TACE decreased IDR compared with TACE alone. Our findings suggest that cisplatin TAI might contribute to a longer progression-free period in unresectable HCC patients treated with TACE.

Introduction

Recently, the number of deaths from hepatocellular carcinoma (HCC) is decreasing in Japan, but it remains that HCC is the tenth most common cancer in the world.¹ HCC’s incidence is especially high in African and Asian countries, including Japan. This is because HCC has a higher incidence in patients with chronic hepatitis B or hepatitis C virus infection, which are highly epidemic in these countries.²

Currently, there is a wide range of HCC treatment methods, including liver transplantation, hepatectomy, radiofrequency ablation (RFA), percutaneous ethanol injection therapy (PEIT), transcatheter arterial chemoembolization (TACE), transcatheter arterial infusion (TAI) chemotherapy, molecular-targeted chemotherapy, and radiotherapy.³ Such treatment methods can be used alone or combined. HCC’s therapy should be selected with consideration for the liver’s underlying clinical condition.

Recently HCC’s treatment outcome has seen improvements. However, approximately 80% of patients who underwent curative resection develop an intrahepatic recurrence. The latter can be due to either intrahepatic metastasis from the primary lesion or multicentric carcinogenesis.⁴

Results of randomized controlled trials and meta-analyses published after 2000 indicate that TACE provides a survival...
benefit for patients with unresectable or relapsed HCC.\textsuperscript{5–8} However, there is a very high incidence of synchronous/asynchronous multicentric carcinogenesis and early-stage intrahepatic metastasis. This is because HCC is predominantly associated with chronic hepatic disorders. The recurrence rate of stage I/II HCC 1 year and 2 years after RFA is 25\%\textsuperscript{9} and 42\%,\textsuperscript{10} respectively. Additionally, TACE has not been consistently useful for long-term HCC treatment due to intrahepatic distant recurrence (IDR).

Few studies have reported on the effectiveness of additional chemotherapy combined with TACE to prevent IDR of HCC. Specifically, Ishikawa \textit{et al.} compared the efficacy of TAI with cisplatin and TAI with carboplatin combined with curative treatment (RFA and/or TACE) to prevent IDR of the stage I/II HCC patients.\textsuperscript{11} They demonstrated that cisplatin obtained a significantly lower IDR rate compared with carboplatin. Based on these results, the authors concluded that cisplatin reduced IDR more effectively compared with carboplatin. In a retrospective study, Kim \textit{et al.} evaluated the efficacy of arterial cisplatin infusion following TACE in patients with advanced HCC who had hepatic vein invasion and Child–Pugh class A.\textsuperscript{12} The authors concluded that significant prolonged survival was observed in patients accompanied with cisplatin TAI. However, to date no reports are available on the effect of TAI with cisplatin combined with TACE to prevent IDR of HCC compared with TACE alone. In advanced HCC patients, including Child–Pugh class A and B, and stage III/IV with and without invasion in hepatic vein.

The aim of the present study was to investigate the efficacy of TAI with cisplatin combined with TACE for preventing IDR of HCC vs TACE alone in patients with unresectable HCC.

\section*{Methods}

\textbf{Patients.} We performed a single-center, retrospective cohort study. Specifically, we evaluated the efficacy of the first TACE combined with TAI using cisplatin (TACE with TAI) vs that of the first TACE without TAI (TACE alone) to prevent IDR of HCC. We considered including consecutive patients diagnosed as unresectable HCC and treated with TACE with epirubicin in this study. Patients were evaluated between April 2005 and March 2014 at Fujita Health University Hospital. In this period, the attending physicians decided the treatment method of TAI with cisplatin followed by TACE with epirubicin or TACE with epirubicin alone depending on the condition of each patient, mainly renal function considering the side effect of cisplatin. The liver function of the patients did not have significant difference between two groups.

Each patient had to meet the following criteria: previously untreated HCC or recurrent HCC after curative hepatectomy, RFA or PEIT, HCC for which neither hepatectomy nor local therapy (RFA or PEIT) was applicable, no extrahepatic metastasis, and an Eastern Cooperative Oncology Group performance status of 0–2. Tumor node metastasis (TNM) stage, which was determined as previously reported in studies for staging of HCC conducted by the Liver Cancer Study Group of Japan (LCSGJ),\textsuperscript{13} was used for evaluation of tumor progression.

Finally, 44 and 24 consecutive patients who underwent TAI with cisplatin followed by TACE with epirubicin and TACE with epirubicin alone were included in this study, respectively. Multivariate analysis identified the independent risk factors associated with IDR. There was selection bias between two groups, so a propensity score analysis was used for adjusting for the differences of baseline characteristics between the TACE+TAI group and TACE alone group as described in statistical analysis.

The ethics committee on human research of Fujita Health University approved this study. Each patient provided informed consent. The study protocol conformed to the guidelines of the 1996 revision of the Declaration of Helsinki.

\textbf{TACE and TAI.} TACE was performed based on the following steps. A catheter was inserted into the feeding artery. There we monitored a densely stained tumor using angiography. An epirubicin-lipiodol suspension (a mixture of 5 mL of lipiodol and 5 mL of a contrast medium containing 50 mg of epirubicin) was injected until the blood flow in the target artery stagnated according to the tumor size. The hepatic artery was embolized with porous gelatin particles from the feeding artery based on the tumor size and vascular diameter.

In the TACE+TAI group, a catheter was placed in proper hepatic artery. The cisplatin fine powder formulation (IA-call; Nippon Kayaku, Tokyo, Japan) was solubilized in saline, at a concentration of 100 mg/70 mL, immediately prior to use. Cisplatin was administered for the whole liver from the proper hepatic artery with a total dose of 65 mg/m\textsuperscript{2}. TACE with epirubicin was subsequently performed as mentioned above.

\section*{Study endpoint and evaluation of therapeutic response.} The present study defined IDR as the primary endpoint. According to Ishikawa \textit{et al.}’s definition, IDR was determined as a new recurrent HCC occurring in another subsegment away from the area of previously treated HCC.\textsuperscript{11} The local recurrence was defined as the recurrence in the same subsegment with tumors underwent TACE. Because local recurrence before IDR may affect IDR, the overall local recurrence rates before IDR were evaluated in TACE alone group and in TACE+TAI group among patients with complete response.

Evaluation of therapeutic response of TACE was used enhanced CT results obtained at 1–2 months after TACE, in accordance with the modified RECIST guideline.\textsuperscript{14,15} After the first evaluation, the follow-up interval of CT scan is 1–3 months depending on the therapeutic response and the condition of the patients.

\section*{Statistical analysis.} Statistical analysis was conducted using the SAS 6.10 software (SAS Institute, Cary, NC, USA). Variables with a normal distribution were expressed as mean values ±SD, and asymmetrically distributed data were expressed as median and interquartile range (IQR). The differences between the two groups were evaluated by Student’s \textit{t}-test or Mann–Whitney \textit{U} test for continuous variables and the chi-square test for categorical variables. Differences in the IDR rate between two groups were examined with the Kaplan–Meier method. Additionally, they were compared using a log-rank test. Hazard ratios (HR) and 95\% confidence intervals (CI) were calculated for each factor by a Cox proportional hazards analysis.

To adjust for the differences of baseline characteristics between two groups, a propensity score analysis was performed using multivariate logistic regression model including gender,
age, and all baseline variables with significant differences between two groups. The score was subsequently incorporated into Cox proportional hazards model as a covariate. Furthermore, propensity score-adjusted survival curves were also constructed. Finally, to determine independent predictors for the endpoints, we used Cox multivariate model that consisted of all covariates with $P < 0.05$ on the univariate analysis with propensity score. Specifically, the latter consisted of all covariates with $P < 0.05$ on the univariate analysis with propensity score. We considered differences with a $P < 0.05$ as statistically significant. The propensity score adjusting was performed because the number of patients was small in this study. The propensity score was used as a covariate not to decrease the number. The baseline characteristics after matching cannot be shown because matching with the propensity score was not performed in this study.

Results

Baseline characteristics. Baseline characteristics are described in Table 1. The prevalence of stage IV was significantly higher in TACE+TAI group than in TACE alone group (13.6 vs 0.0%, $P = 0.023$). Inversely, we observed that TACE+TAI group had lower prevalence of previous treatment (36.4 vs 70.8%, $P = 0.0066$), serum creatinine levels (0.75 ± 0.22 mg/dL vs 1.02 ± 0.41 mg/dL., $P = 0.0009$), and dose of EPI (20 ± 14 mg vs 34 ± 29 mg, $P = 0.010$) compared with TACE group. Other characteristics were comparable between two groups.

### Table 1  Baseline characteristics

|                          | All patients ($n = 68$) | TACE alone ($n = 24$) | TACE + TAI ($n = 44$) | $P$ value |
|--------------------------|-------------------------|-----------------------|-----------------------|-----------|
| Gender (male/female)     | 51/17                   | 20/4                  | 31/13                 | 0.24      |
| Age (years)              | 71 ± 8                  | 72 ± 6                | 70 ± 9                | 0.42      |
| Etiology of liver disease (HBV/HCV/NBNC) | 5/50/13               | 3/18/3                | 2/32/10               | 0.33      |
| Previous treatment (surgical/local/non) | 3/20/35         | 2/15/7                | 1/15/28               | 0.0066    |
| Child–Pugh class (AB)    | 43/23                   | 15/8                  | 28/15                 | 0.91      |
| Child–Pugh score (5/6/7/8/9) | 28/15/10/12/1 | 11/4/4/3/1            | 17/11/6/9/0           | 0.61      |
| Stage (I/II/III/IV/A)    | 7/22/33/6               | 5/5/14/0              | 2/17/19/6             | 0.023     |
| Vp (–/+                  | 59/6                    | 23/1                  | 36/5                  | 0.45      |
| Number of tumor (1/2/3>3) | 15/6/4/2               | 6/3/1/4/1             | 9/3/3/2/8             | 0.73      |
| Tumor diameter (mm)      | 31.1 ± 15.5             | 27.2 ± 14.5           | 33.2 ± 15.7           | 0.13      |
| AFP (mg/mL)              | 48 (11–212)             | 52 (17–193)           | 44 (11–213)           | 0.52      |
| DCP (mAU/mL)             | 89 (27–682)             | 52 (23–1072)          | 105 (30–682)          | 0.56      |
| Creatinine (mg/dL)       | 0.85 ± 0.32             | 1.02 ± 0.41           | 0.75 ± 0.22           | 0.0009    |
| Platelets (×10^9/mm^3)   | 9.9 ± 4.6               | 10.3 ± 4.7            | 9.8 ± 4.6             | 0.64      |
| ALT (IU/mL)              | 58 ± 45                 | 65 ± 63               | 54 ± 32               | 0.31      |
| AST (IU/mL)              | 66 ± 38                 | 65 ± 39               | 67 ± 37               | 0.81      |
| Albumin (g/dL)           | 3.5 ± 0.5               | 3.6 ± 0.5             | 3.5 ± 0.5             | 0.19      |
| Total bilirubin (mg/dL)  | 1.3 ± 0.7               | 1.1 ± 0.7             | 1.3 ± 0.6             | 0.19      |
| Prothrombin time (%)     | 75.1 ± 11.5             | 73.3 ± 11.9           | 76.1 ± 11.5           | 0.34      |
| Dose of epirubicin (mg)  | 25 ± 24                 | 34 ± 29               | 20 ± 14               | 0.010     |
| Dose of lipiodol (mL)    | 7.3 ± 4.3               | 7.1 ± 4.2             | 7.3 ± 4.4             | 0.85      |

$P$ values represent the results of the comparison between TACE alone group and TACE with TAI group.

As we indicated in Table 1, Child–Pugh score and Child–Pugh classification of the patients did not have significant difference between two groups. There were no significant differences in The Barcelona classifications between two groups.

AFP was higher in the TACE group vs TAI/TACE group without significant difference, and the distribution of AFP between the two groups did not have significant difference between two groups.

Treatment effects. Tumor responses 1–2 months after TACE are summarized in Table 2. Tumor responses, objective response rate (ORR), and disease control rate (DCR) 1–2 months after TACE were comparable between two groups ($P = 0.89, P = 0.94, P = 0.94$, respectively).

Overall, local recurrence rates before IDR were 9.1% in TACE alone group, and 10.5% in TACE+TAI group among patients with complete response. Local recurrence rates before IDR had no significant differences between TACE+TAI group and TACE alone group.

Intrahepatic distant recurrence rates. The cumulative IDR rates, by Kaplan–Meier analysis, at 1 and 3 years were 76.7 and 76.7% in TACE group, and 21.3 and 73.2% in TACE+TAI group, respectively. The TACE alone group had a significantly higher IDR rate compared with TACE+TAI group ($P = 0.0071$). Furthermore, median IDR-free time was 6.5 months in TACE alone group and 21.4 months in TACE+TAI group ($P < 0.0001$).
Table 2  Tumor responses 1–2 months after transcatheter arterial chemoembolization (TACE)

| Response | TACE alone (n = 24) | TACE + TAI (n = 44) | P value |
|----------|--------------------|---------------------|---------|
| CR       | 11 (45.8%)         | 19 (43.2%)          | 0.89    |
| PR       | 9 (37.5%)          | 18 (40.9%)          |         |
| SD       | 3 (12.5%)          | 5 (11.4%)           |         |
| PD       | 1 (4.2%)           | 2 (4.5%)            |         |
| ORR (CR + PR) | 20 (83.3%)       | 37 (84.1%)          | 0.94    |
| DCR (CR + PR) | 23 (95.8%)       | 42 (95.5%)          | 0.94    |

CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TACE, transcatheter arterial chemoembolization.

Predictors of intrahepatic distant recurrence. By means of the Cox univariate analysis, we identified the following characteristics as IDR predictors: combined with TAI (HR 0.39, 95% CI 0.19–0.79, P = 0.0093), Stage ≥III (HR 2.29, 95% CI 1.09–4.84, P = 0.029), creatinine levels (HR 1.11, 95% CI 1.01–1.23, P = 0.030), and dose of epirubicin (HR 1.02, 95% CI 1.00–1.03, P = 0.023) (Table 3).

Of note, combined with TAI was associated with preventing IDR even after propensity score-adjusting (HR 0.40, 95% CI 0.17–0.91, P = 0.028, Table 3). Adjusted cumulative IDR rates at 1 and 3 years were 76.8 and 76.8% in TACE alone group, 21.3 and 73.1% in the TACE+TAI group, respectively (Fig. 1). The IDR rate was significantly lower in TACE+TAI group compared with TACE group (P = 0.0073).

After adjusting for significant risk factors with propensity score including Stage and previous treatment, independent IDR predictors were combined with TAI (HR 0.26, 95% CI 0.10–0.68, P = 0.0056) and Stage ≥III (HR 2.98, 95% CI 1.25–7.12, P = 0.014) (Table 4).

There were not enough cases to compare the overall survival as an endpoint, because many enrolled patients’ prognoses could not be confirmed since they were transferred from our hospital to other hospitals at the end stage of HCC. For the same reason, we could not show how many cases died from cancer after confirmation of recurrence.

Adverse events. The adverse events related with the treatment were assessed according to the National Cancer Institute Common Terminology Criteria, version 4.0. We evaluated the adverse events as the maximum change in the grade within 1 month post-treatment. Neither group developed adverse events of Grade 3 or 4.

We observed no differences among the two groups in terms of both adverse events caused by the treatments and laboratory tests post-treatment. No specific adverse events were identified in two groups.

We observed temporary elevations of creatinine, total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels, as well as temporary declines in the platelet count and albumin levels. These laboratory test values changed similarly in both groups. It should be noted that the tests returned to their pretreatment levels 2 months post-treatment. Additionally, Child–Pugh scores changed similarly in both groups, and hepatic reserve capacity was temporarily reduced but returned to its pretreatment levels 2 months post-treatment (Table 5).

Table 3  Predictors for intrahepatic distant recurrence by univariate Cox analysis

| Predictor                  | Hazard ratio | 95% confidence interval | P value |
|----------------------------|--------------|-------------------------|---------|
| Combination with TAI       | 0.39         | 0.19–0.79               | 0.0093  |
| Male                       | 1.21         | 0.55–2.69               | 0.64    |
| Age (per 1 year)           | 1.02         | 0.97–1.07               | 0.36    |
| HCV versus HBV or NBNC     | 1.45         | 0.63–3.34               | 0.39    |
| Previous treatment         | 0.98         | 0.49–1.94               | 0.95    |
| Child–Pugh class (A versus B) | 1.13       | 0.52–2.46               | 0.76    |
| Stage ≥III                 | 2.29         | 1.09–4.84               | 0.029   |
| Number of tumors >3        | 1.84         | 0.86–3.96               | 0.12    |
| Tumor diameter (per 1 mm)  | 1.01         | 0.98–1.03               | 0.53    |
| AFP > 48 ng/mL             | 1.02         | 0.48–2.16               | 0.96    |
| DCP > 89 mAU/mL            | 1.24         | 0.59–2.61               | 0.56    |
| Creatinine (per 0.1 mg/dL) | 1.11         | 1.01–1.23               | 0.030   |
| Platelets (per 1 × 10^5/mm^3) | 1.01   | 0.95–1.09               | 0.69    |
| ALT (per 1 IU/mL)          | 1.01         | 0.99–1.01               | 0.51    |
| AST (per 1 IU/mL)          | 1.00         | 0.99–1.01               | 0.87    |
| Albumin (per 1 g/dL)       | 0.83         | 0.42–1.62               | 0.57    |
| Total bilirubin (per 1 mg/dL) | 1.05  | 0.57–1.92               | 0.88    |
| Prothrombin time (per 1%)  | 1.01         | 0.98–1.04               | 0.49    |
| Dose of epirubicin (per 1 mg/L) | 1.02  | 1.00–1.03               | 0.023   |
| Dose of lipiodol (per 1 mL) | 1.02         | 0.94–1.12               | 0.61    |

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCP, des-gamma-carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, both negative for HBV and HCV; TAI, transcatheter arterial infusion.
Discussion

This is the first study demonstrating that TAI with cisplatin combined with TACE decreased IDR, compared with TACE alone, for unresectable HCC with and without hepatic vein invasion and including Child–Pugh class A and B. Our results suggest additional TAI with cisplatin may contribute to a longer progression-free period for patients treated with TACE for unresectable HCC.

Nowadays, many systematic chemotherapies for HCC are being studied in clinical trials. These include multiple tyrosine kinase inhibitors and immune checkpoint inhibitors. Unresectable HCC patients can now be administered sorafenib, regorafenib, lenvatinib, and ramucirumab in Japan. However, such systemic chemotherapeutic agents are limited to those patients with very good liver reserve function as only Child–Pugh class A. Specifically, many patients with HCC have underlying chronic liver diseases and declining liver function, so these systematic chemotherapies cannot be used for many HCC patients. Therefore, TACE still has very important position in the treatment strategy of unresectable HCC, especially for patients with poor liver reserve function as Child–Pugh class B.

Table 4 Predictors for intrahepatic distant recurrence by multivariate cox analysis

| Predictor                  | Propensity score-adjusted | Risk-adjusted with propensity score |
|----------------------------|---------------------------|-------------------------------------|
|                            | HR (95% CI)               | P value                             | HR (95% CI) | P value                             |
| Combination with TAI       | 0.40 (0.17–0.91)          | 0.028                               | 0.26 (0.10–0.68) | 0.0056 |
| Stage > III                |                           |                                     | 2.98 (1.25–7.12) | 0.014 |
| Creatinine                 |                           |                                     | 1.13 (0.96–1.33) | 0.13 |
| Dose of epirubicin         |                           |                                     | 1.01 (0.99–1.02) | 0.26 |

CI, confidence interval; HR, hazard ratio; TAI, transcatheter arterial infusion.
However, there are currently no reports on the efficacy of TAI combined with TACE compared with TACE alone in patients with advanced HCC including Stage III/IV, with and without hepatic vein invasion, and including Child–Pugh class A and B. In the present study, we demonstrate that TAI with cisplatin combined with TACE decreased IDR compared with TACE alone in such condition of patients. These results prove the efficacy of TAI with cisplatin combined with TACE to prevent IDR of HCC under various conditions.

Ishikawa et al. also reported that TAI using cisplatin in combination with TACE using miriplatin (Miripla; Dainippon Sumitomo Pharma, Osaka, Japan) improved survival compared with TAI using cisplatin accompanied with TACE using epirubicin in patients with HCC intermediate stage B of Barcelona Clinic Liver Cancer (BCLC) classification. They evaluated whether epirubicin or miriplatin best contributed to survival in TACE agents in combination with cisplatin TAI in primary HCC patients with BCLC-B. However, they did not compare the efficacy or survival between TACE with TAI and TACE alone. The results of the present study are important because our data provide fundamental basic information and supplement their results.

Kamimura et al. demonstrated a randomized trial for evaluating the effect of TAI using combination of miriplatin and cisplatin versus miriplatin alone. They reported that the combination therapy of miriplatin and cisplatin had significantly better progression-free survival and overall DCR. Recently, as miriplatin has become the standard drug in addition to anthracyclines in TACE in Japan, the results of the present study also provide useful basic information whether to add TAI using cisplatin to TACE using miriplatin in the future.

As to the adverse events caused by the treatments, no differences between TACE+TAI patients compared with TACE alone patients were observed. Additionally, no specific adverse events were identified in TACE+TAI patients compared with TACE alone patients. This is a retrospective study, which caused a selection bias between the two groups, particularly in renal function. Nevertheless, TAI with cisplatin in combination with TACE was able to be carried out safely just as TACE alone.

Several limitations can be identified in the present study. Primarily, this was a single-center study with a limited number of patients. Secondly, this study was a retrospective cohort study, not a prospective randomized study. As a result, there might be confounding or residual selection bias in spite of propensity score adjustments. Thirdly, this study did not set the overall survival as an endpoint. This was because many enrolled patients’ prognoses could not be confirmed since they were transferred from our hospital to other hospitals at the end stage of HCC. For the same reason, we could not show how many cases died from cancer after confirmation of recurrence. Therefore, our results should be considered in further investigations.

However, there are numerous patients with unresectable HCC treated with TACE since novel effective systemic chemotherapies have limited indications for patients who have good hepatic reserve function as Child–Pugh class A. Therefore, there is high need to further improve TACE’s therapeutic effect to satisfy the unmet needs of patients with contraindications for effective systemic chemotherapies.

Our findings suggest that TAI with cisplatin might have a contribution to a longer progression-free period for patients treated with TACE for unresectable HCC. Additionally, these results will contribute to future clinical practice and clinical trials.

**Table 5** Changes in laboratory data before and 2 months after treatment

|                      | TACE alone | TACE with TAI |
|----------------------|------------|---------------|
|                      | Baseline   | 2 months after|      |
| Creatinine (mg/dL)   | 1.02 ± 0.41| 1.00 ± 0.32   | 0.54 |
| Platelets (×10^3/mm^3)| 10.3 ± 4.7 | 8.3 ± 4.6     | 0.21 |
| ALT (IU/mL)          | 65 ± 63    | 47 ± 42       | 0.17 |
| AST (IU/mL)          | 65 ± 39    | 50 ± 38       | 0.16 |
| Albumin (g/dL)       | 3.6 ± 0.5  | 3.5 ± 0.4     | 0.48 |
| Total bilirubin (mg/dL)| 1.1 ± 0.7 | 1.1 ± 0.6     | 0.65 |
| Prothrombin time (%) | 73.3 ± 11.9| 75.8 ± 12.2   | 0.43 |
| Child–Pugh Score     | 6.1 ± 1.7  | 6.2 ± 1.8     | 0.39 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TACE, transcatheter arterial chemoembolization; TAI, transcatheter arterial infusion.

**REFERENCES**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. *Int. J. Cancer*. 2010; 127: 2893–917.
2. Okuda K. Hepatocellular carcinoma. *J. Hepatol*. 2000; 32: 225–37.
3. Yamashita T, Kaneko S. Treatment strategies for hepatocellular carcinoma in Japan. *Hepatol. Res.* 2012; 43: 44–50.
4. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. *Ann. Surg.* 2000; 232: 10–24.
5. Llovet JM, Real MI, Montanà X et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. *Lancet*. 2002; 359: 1734–9.
Recurrence of hepatocellular carcinoma following combined radiochemical therapy: A 10-year outcome and prognostic factors. *Am. J. Gastroenterol.* 2012; 107: 569–77.

Nojiri S, Kusakabe A, Shinkai N. Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C. *Cancer Manag. Res.* 2011; 3: 267–72.

Ishikawa T, Higuchi K, Kubota T. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. *Cancer.* 2011; 117: 4018–25.

Kim HC, Lee JH, Chung JW et al. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. *J. Vasc. Interv. Radiol.* 2013; 24: 274–83.

The Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 6th edn. Tokyo: Kanehara, 2015; 26.

Eisenhauer EA, Therasse P, Bogart J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur. J. Cancer.* 2009; 45: 228–47.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin. Liver Dis.* 2010; 30: 52–60.

Chau I, Peck-Radosavljevic M, Borg C et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. *Eur. J. Cancer.* 2017; 81: 17–25.

Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N. Engl. J. Med.* 2018; 379: 54–63.

Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol.* 2018; 19: 940–52.

El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet.* 2017; 389: 2492–502.

Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* 2008; 359: 378–90.

Bruijx J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2017; 389: 56–66.

Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet.* 2018; 391: 1163–73.

Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019; 20: 282–96.

Zhu AX, Baron AD, Malferttheiner P et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score. *JAMA Oncol.* 2017; 3: 235–43.

Aoyama K, Tsukishiro T, Okada K et al. Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. *Cancer Chemother. Pharmacol.* 1992; 31: S55–9.

Ichida T, Kato M, Hayakawa A et al. Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension: a pilot clinicopharmacological study. *Cancer Chemother. Pharmacol.* 1992; 31: S51–4.

Colleoni M, Gaion F, Liessi G, Mastropasqua G, Nelli P. Arterial chemoembolization with epirubicin in unresectable hepatocellular carcinoma in cirrhosis. *Oncol. Rep.* 1994; 1: 1171–5.

Tommasini M, Colombo M, Sangiovanni A et al. Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis. *Am. J. Clin. Oncol.* 1986; 9: 8–11.

Ohnishi K, Tsuchiya S, Nakayama T et al. Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. *Radiology.* 1984; 152: 51–5.

Sasaki Y, Imaoka S, Kasugai H et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. *Cancer.* 1987; 60: 1194–203.

Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. *Jpn. J. Clin. Oncol.* 2012; 42: 247–55.

Kasugai H, Kojima J, Tatsuta M et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. *Gastroenterology.* 1989; 97: 965–71.

Bronowicki JP, Vetter D, Dumas F et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. *Cancer.* 1994; 74: 16–24.

Kawai S, Tani M, Okamura J et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. *Semin. Oncol.* 1997; 24: S6–38–45.

Court WS, Order SE, Siegel JA et al. Remission and survival following monthly intra-arteral cisplatinum in nonresectable hepatoma. *Cancer Invest.* 2002; 20: 613–25.

Ishikawa T, Abe S, Watanabe T et al. Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma. *Mol. Clin. Oncol.* 2016; 5: 511–6.

Kamimura K, Suda T, Yokoo T et al. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. *BMC Cancer.* 2017; 17: 322.

Ikeda K. Recent advances in medical management of hepatocellular carcinoma. *Hepatol. Res.* 2019; 49: 14–32.

Kubota K, Hidaka H, Nakazawa T et al. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. *Hepatol. Res.* 2018; 48: E98–E106.

Ikeda M, Kudo M, Aikata H et al. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. *J. Gastroenterol.* 2018; 53: 281–90.